Mens 2008 KEN.

Methods	Trial design: An open label RCT Follow‐up: Malaria film and Hb level on days 0, 1, 2, 3, 7, 14, and 28, plus QT‐NASBA for detection of sub‐microscopic gametocytaemia Adverse event monitoring: Adverse events were recorded at each visit in the case record form. An adverse event defined as any unfavourable and unintended sign.
Participants	Number of participants: 146 Inclusion criteria: Age 6 months to 12 years, axillary temp > 37.5 °C or history of fever, P. falciparum mono‐infection 1000 to 200,000/µL, informed consent Exclusion criteria: Severe malaria, any other underlying illness
Interventions	1. DHA‐P, fixed dose combination, 20 mg/160 mg tablets (Sigma‐Tau) 4 to 7 kg ½ tablet once daily for 3 days 7 to 13 kg 1 tablet once daily for 3 days 13 to 24 kg 2 tablets once daily for 3 days 24 to 35 kg 4 tablets once daily for 3 days 2. Artemether‐lumefantrine, fixed dose combination, 20/120 mg tablets (Novartis) 5 to 14 kg 1 tablet twice daily for 3 days 15 to 24 kg 2 tablets twice daily for 3 days 25 to 34 kg 3 tablets twice daily for 3 days All doses supervised and given with a glass of milk.
Outcomes	Recurrent parasitaemia at day 28, PCR‐adjusted and PCR‐unadjusted Gametocyte prevalence during follow‐up Mean Hb at day 28 Adverse events Not included in this review: Fever clearance Parasite clearance
Notes	Country: Kenya Setting: Health centre Transmission: High transmission Resistance: Not reported Dates: Apr 2007 to Jul 2007 Funding: The Knowledge and Innovation Fund, Koninklijk Instituut voor de Tropen/Royal Tropical Institute. DHA‐P provided free of charge by Sigma‐Tau.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"A computer generated randomisation list".
Allocation concealment (selection bias)	Unclear risk	None described.
Blinding for microscopy outcomes (performance bias and detection bias)	Low risk	Microscopists were blinded to treatment allocation.
Blinding for adverse events (performance and detection bias)	Unclear risk	No other blinding described.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Low losses to follow‐up in both groups (8.2% DHA‐P versus 8.2% AL6).
Selective reporting (reporting bias)	Low risk	The WHO recommends 42 days follow‐up in studies of AL6. Day 28 outcomes may underestimate treatment failure with AL6 and DHA‐P.
Other bias	Low risk	No other sources of bias identified.